Main mutations in the hepatitis B virus basic core promoter (A1762T/G1764A) before HBeAg loss are markers that identify patients who will require long-term treatment

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 1, 2010, Pages 97-104

  Tabernero, D ^a,b   Sanchez M J ^b   Homs, M ^a,b   Rodriguez Frias F ^a,b   Jardi R ^a,b   Schaper, M ^a,b   Esteban, R ^a,b   Buti, M ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE LOSS; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROMOTER REGION; SEROCONVERSION; SEROLOGY; SEX DIFFERENCE; VIREMIA; VIROLOGY; VIRUS DETECTION; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; TIME FACTORS; YOUNG ADULT;

EID: 77953215683     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04319.x     Document Type: Article

References (30)

1. EASL Clinical Practice Guidelines. Management of chronic hepatitis B. J Hepatol 2009 50 : 227 242.
2. Lok AS, McMahon BJ. AASLD practice guidelines. Chronic Hepatitis B. Hepatology 2007 2 : 507 539.
3. Chu CJ, Hussain M, Lok ASF. Quantitative serum HBV levels during different stages of chronic hepatitis B infection. Hepatology 2002 36 : 1408 1415.
4. Liaw YF, Chu CM, Huang MJ, Sheen IS, Yang CY, Lin DY. Determinants for hepatitis B e antigen clearance in chronic type B hepatitis. Liver 1984 4 : 301 306.
5. Buckwold VE, Xu Z, Chen M, et al. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996 70 : 5845 5851.
6. Buti M, Jardi R, Rodríguez-Frías F, et al. Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen patients with chronic hepatitis B: the effect of long-term lamivudine therapy. Aliment Pharmacol Ther 2005 21 : 1349 1356.
7. Yuan HJ, Yuen MF, Ka-Ho W, et al. Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B. Aliment Pharmacol Ther 2005 22 : 301 307.
8. Hsu YS, Cjien RN, Yeh CT, et al. Long term outcome spontaneous HBeAg Seroconversion in Patients with Chronic Hepatitis B. Hepatology 2002 35 : 1522 1527.
9. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008 57 : 84 90.
10. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum 341 hepatitis B virus DNA level. JAMA 2006 295 : 65 73.
11. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 130 : 678 686.
12. Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008 134 : 405 415.
13. Wu IC, Shiffman ML, Tong MJ, et al. Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. Clin Infect Dis 2008 47 : 1305 1311.
14. Yuen MF, Sablon E, Yuan HJ, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis 2002 186 : 1335 1338.
15. Ferns RB, Naoumov N, Gilson R, Tedder RS. Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss. J Clin Virol 2007 39 : 199 204.
16. Jardi R, Rodriguez F, Buti M, et al. Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay. J Viral Hepat 2001 8 : 465 471.
17. Jardi R, Rodriguez-Frias F, Tabernero D, et al. Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy. J Clin Microbiol 2009 47 : 485 488.
18. Okamoto H, Tsuda F, Sakugawa H, et al. Typing Hepatitis B Virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988 69 : 2575 2583.
19. Pichoud C, Berby F, Stuyver L, Petit MA, Trépo C, Zoulim F. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J Hepatol 2000 32 : 307 316.
20. Tangkijvanich P, Kolomit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009 46 : 117 123.
21. Janssen HL, van Zonneveld M, Sentruk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005 365 : 123 129.
22. Kramvis A, Kew MC. The core promoter of hepatitis B virus. J Viral Hepat 1999 6 : 415 427.
23. Jardi R, Rodriguez F, Buti M, et al. Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. J Hepatol 2004 40 : 507 514.
24. Locarnini S. Relevance of HBV mutations in severity and progression of chronic hepatitis B. J Gastroenterol Hepatol 2004 19 : S108 12.
25. Jang JW, Lee YC, Kim MS, et al. A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis. J Viral Hepat 2007 14 : 169 175.
26. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet 1989 2 : 588 591.
27. Yuen MF, Yuan HJ, Hui CK, Wong DKH. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003 52 : 416 419.
28. Gunther le S, Piwon N, Will H. Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653)→ T, A (1762) →T and G (1764) → A mutations in the core promoter. J Gen Virol 1998 79 : 375 380.
29. Akahane Y, Yamanaka T, Susuki H, et al. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum: disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990 99 : 1113 1119.
30. Marrone A, Zampino R, Karayannis P, et al. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis. Aliment Pharmacol Ther 2005 22 : 707 714.